Home › Autoimmune Diseases › Indiana › Indianapolis
Autoimmune Diseases clinical trials in Indianapolis, IN
4 studies for Autoimmune Diseases are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Innovative Hematology, Inc., Indianapolis
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Innovative Hematology, Inc., Indianapolis
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RecruitingPhase 2/3
- Indiana University Health, Indianapolis
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Indiana University/Riley Hospital for Children, Indianapolis
About Autoimmune Diseases
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
More about Autoimmune Diseases on MedlinePlus
Autoimmune Diseases trials in other cities
- Houston, TX21 studies
- Washington, DC19 studies
- New York City, NY19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Boston, MA13 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Cleveland, OH8 studies
- Milwaukee, WI8 studies
- Atlanta, GA8 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure23 studies
- Breast Cancer20 studies
- Obesity20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Lung Cancer16 studies
- Cardiovascular Disease16 studies
- Type 1 Diabetes14 studies
- Endometrial Cancer14 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.